FDA Approves Lynparza for Certain Advanced Ovarian Cancer

The FDA approved olaparib (Lynparza, AstraZeneca and Merck) for maintenance treatment of adults with certain genetic types of ovarian cancer.

Olaparib is indicated for patients with deleterious or suspected deleterious germline or somatic BRCA gene–mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, who have complete or partial response to first-line platinum-based chemotherapy. 

Patients with gBRCAm advanced epithelial ovarian,